Cardeas Pharma Secures $34,000,000 Series B Funding Round

  • Feed Type
  • Date
    5/23/2013
  • Company Name
    Cardeas Pharma
  • Mailing Address
    2025 First Avenue Seattle, WA 98121
  • Company Description
    Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae.
  • Website
    http://www.cardeaspharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $34,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Funds from this financing will be used to support Phase 2 development of Cardeas’ lead compound, investigational amikacin/fosfomycin inhalation solution delivered via an eFlow InLine Nebulizer system, as a potential treatment for healthcare associated pneumonia (HCAP) in patients on mechanical ventilation.
  • M&A Terms
  • Venture Investor
    H.I.G. Capital
  • Venture Investor
    Novo Ventures
  • Venture Investor
    Avalon Ventures
  • Venture Investor
    WRF Capital
  • Venture Investor
    De Novo Ventures
  • Venture Investor
    Devon Park Bioventures

By posting a comment, you agree to our terms and conditions.